Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases

Tianjin Medical University

Status: Enrolling

Conditions: Metastasis; CXCR4-related Disease; Tumor; Positron Emission Tomography

Treatments: Diagnostic Test: CXCR4 PET/CT Imaging

Study type: Interventional

Funder types: Other

Identifiers

NCT06690736

TJMUGH-02

Details and patient eligibility

About

To evaluate the potential usefulness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.

Full description

Subjects with various CXCR4-related disease patients underwent 68Ga/18F-Pentixafor/Pentixather PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga/18F-Pentixafor/Pentixather PET/CT were calculated.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients
• 18F-FDG PET/CT within two weeks
• signed written consent.

Exclusion criteria

• pregnancy
• breastfeeding
• known allergy against Pentixafor

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

200 participants in 1 patient group

CXCR4 PET/CT Imaging

Experimental group

Description:

Intravenous injection of one dose of 2-5 mCi 68Ga/18F-Pentixafor/Pentixather. Tracer doses of radiotracers will be used to image lesions by PET/CT

Treatment:

Diagnostic Test: CXCR4 PET/CT Imaging